Form4insider filings, from the source

SEC Form 4 · accession 0001363763-17-000002

RespireRx Pharmaceuticals Inc. · RSPI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
James S J Manuso
Officer — Preident & CEO · Director
Period of report
Jan 18, 2017
Accepted (ET)
Jan 20, 2017 · 9:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000849636

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Common Stock Options (to purchase shares of Common Stock)F1$3.90Jan 18, 2017A75,000A—Jan 18, 2017Common Stock75,00075,000D
Common Stock Warrants (right to buy)F2$4.875holding———Apr 7, 2016Sep 30, 2020Common Stock36,57836,578D
Common Stock Warrants (right to buy)F2$6.50holding———Feb 4, 2016Feb 4, 2019Common Stock8,0938,093D
Common Stock Options (to purchase shares of Common Stock)F2,F3$7.3775holding————Mar 31, 2021Common Stock81,53981,539D
Common Stock Options (to purchase shares of Common Stock)F2,F4$6.396holding————Aug 18, 2025Common Stock15,63415,634D
Common Stock Options (to purchase shares of Common Stock)F2,F4$6.396holding————Aug 18, 2025Common Stock246,154246,154D

Explanation of responses